| Status | In progress |
| Process | STA 2018 |
| ID number | 1109 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
| Evidence Review Group / Assessment Group | Kleijnen Systematic Reviews Ltd |
Consultees
| Companies sponsors | Zogenix International |
| Others | Department of Health and Social Care |
| NHS Central London CCG | |
| NHS England | |
| NHS West Leicestershire CCG | |
| Welsh Government | |
| Patient carer groups | Brain and Spine Foundation |
| Disability Rights UK | |
| Dravet Syndrome UK | |
| Epilepsy Action | |
| Epilepsy Society | |
| Joint Epilepsy Council | |
| Leonard Cheshire Disability | |
| Muslim Council of Britain | |
| Neurological Alliance | |
| S.T.A.B.L.E (Supporting those affected by Lifelong Epilepsy) | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| SUDEP Action | |
| The Brain Charity | |
| Young Epilepsy | |
| Professional groups | Association of British Neurologists |
| British Neuropathological Society | |
| British Paediatric Neurology Association | |
| Epilepsy Nurses Association | |
| Epilepsy Society | |
| Institute of Neurology | |
| International League Against Epilepsy UK | |
| Neuromodulation Society of UK and Ireland | |
| Primary Care Neurology Society | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Paediatrics and Child Health | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| United Kingdom Clinical Pharmacy Association |
Commentators
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Accord Healthcare (clobazam, topiramate) |
| Atnahs Pharma UK (clobazam) | |
| Aurobindo Pharma - Milpharm (topiramate) | |
| Biocodex (stiripentol) | |
| Desitin Pharma (sodium valproate) | |
| Janssen (topiramate) | |
| Martindale Pharma (clobazam) | |
| Mylan (topiramate) | |
| Rosemont Pharmaceuticals (clobazam) | |
| Sandoz (topiramate) | |
| Sanofi (clobazam, sodium valproate) | |
| Thame Laboratories (clobazam) | |
| Wockhardt UK (sodium valproate) | |
| Zentiva (sodium valproate) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Epilepsy Wales | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| Neurological Alliance of Scotland | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Wales Neurological Alliance | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | British Neurological Research Trust |
| Cochrane Epilepsy Group | |
| Epilepsy Research UK | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 October 2019 | The company have asked NICE to reschedule this appraisal again to better align with the regulatory process and NICE has agreed to this request. We anticipate that the appraisal will now re-start in Spring 2020. |
| 04 January 2019 | Invitation to participate |
| 03 January 2019 | In progress, The appraisal was referred to NICE. |
| 26 July 2018 - 23 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance